Commenting on the news that the Medicines and Healthcare products Regulatory Agency (MHRA) will regulate electronic cigarettes as medicines in the UK from 2016, the ABPI has issued the following statement.
We welcome the decision by the Medicines and Healthcare products Regulatory Agency to regulate e-cigarettes and other nicotine-containing products as non-prescription medicines in the UK from 2016.
Regulation will ensure there is a consistent standard across all licensed products and that e-cigarettes go through vigorous quality and efficacy controls which will make them safer and more effective in reducing the harms of smoking.
ABPI Press OfficeTel: +44 (0) 20 7747 1439 or +44 (0) 20 7747 1436Mobile: +44 (0) 7808 641810 or +44 (0) 7920 597 923 Email: firstname.lastname@example.org
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by Government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.